Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on developing MasterKey therapies that target families of oncogenic mutations in cancer patients. The company's approach is built on a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry, aiming to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and achieve brain penetrance for CNS disease treatment. The core business model revolves around the discovery and development of these small molecule MasterKey inhibitors, with revenue currently generated through upfront payments and potential milestone payments and royalties from licensing agreements, rather than product sales. The company's primary customer segments are patients with genetically defined cancers who have limited treatment options.

The company's lead clinical-stage program is silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor. Silevertinib is being studied in a Phase 2 clinical trial for patients with EGFRm non-small cell lung cancer (NSCLC) and is planned for a randomized Phase 2 trial in newly diagnosed patients with EGFR altered glioblastoma (GBM). In NSCLC, silevertinib is designed to treat both newly diagnosed and recurrent patients by addressing over 50 classical and non-classical oncogenic driver mutations with greater potency than other EGFR TKIs, and uniquely targeting the C797S resistance mutation. The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for silevertinib for the treatment of patients with EGFR mutant C797S-positive NSCLC whose disease has progressed on/after a third-generation EGFR TKI.

Initial data from the Phase 2 trial in 43 frontline NSCLC patients with non-classical EGFR mutations, including 16 patients with brain metastases, showed an Objective Response Rate (ORR by RECIST 1.1) of 60% ¹, with 25 confirmed partial responses and 1 confirmed complete response. The CNS ORR (by RANO-BM) was 86% ², and the disease control rate (DCR) was 91% ³. As of the November 3, 2025 data cutoff, 29 patients ⁴ remained on therapy, with one patient on therapy for over 19 months ⁵. For GBM, silevertinib has shown encouraging CNS activity, with a Phase 1 trial in relapsed/recurrent GBM patients demonstrating clinical activity including 1 confirmed partial response and 8 patients with stable disease among 19 patients with measurable disease ⁶. A Phase 0/1 study in recurrent high-grade glioma also showed silevertinib exceeded the pre-specified threshold for drug concentration in brain tumor tissue and suppressed EGFR signaling.

Another key product candidate is BDTX-4933 (also known as S241656), a highly selective, brain-penetrant RAF MasterKey inhibitor. This program was outlicensed to Servier Pharmaceuticals LLC (Servier) in the first quarter of 2025 ⁷. BDTX-4933 is designed to target broad families of oncogenic BRAF, KRAS, and NRAS alterations. Under the license agreement, Black Diamond Therapeutics received an upfront payment of $70.0 million ⁸ in March 2025 ⁹ and is eligible for up to $710.0 million ¹⁰ in development and commercial sales milestone payments, plus tiered royalties on global net sales. The company is also exploring partnership opportunities for its FGFR2/3 selective development candidate, BDTX-4876.

For the fiscal year ended December 31, 2025, the company reported net income of $22.4 million ¹¹, a significant improvement from a net loss of $69.7 million ¹² for the year ended December 31, 2024. As of December 31, 2025, the accumulated deficit was $464.7 million ¹³. The company had cash, cash equivalents, and investments of $128.7 million ¹⁴ as of December 31, 2025. The shift from a net loss to net income year-over-year is primarily attributable to the upfront payment received from the Servier Agreement.

During the reported period, a significant operational development was the outlicensing of BDTX-4933 to Servier in the first quarter of 2025, which included an upfront payment of $70.0 million. The company also completed enrollment in the Phase 2 frontline NSCLC cohort in July 2025 ¹⁵ and announced initial clinical data in December 2025 ¹⁶. Feedback on the study design for the randomized Phase 2 trial in newly diagnosed EGFR-altered GBM patients was received from the FDA in January 2026 ¹⁷, with trial initiation planned for the second quarter of 2026 ¹⁸. In December 2025, the company entered into a sublease for approximately 11,139 square feet ¹⁹ of its Cambridge, MA office space, which terminates on August 31, 2028 ²⁰.

Management plans to initiate a randomized Phase 2 trial of silevertinib in newly diagnosed patients with EGFR altered glioblastoma (GBM) in the second quarter of 2026 ²¹. This trial is expected to enroll approximately 150 newly diagnosed patients ²², randomized to receive temozolomide (TMZ) as the control arm or silevertinib plus TMZ as the experimental arm. The primary endpoint will be progression-free survival (PFS) by blinded independent committee review (BICR), with an interim PFS analysis anticipated in the first half of 2028 ²³. The secondary endpoint will be overall survival (OS).

A major growth area for the company is the continued development of silevertinib in EGFRm NSCLC. Management expects to present updated results from the Phase 2 NSCLC trial, including preliminary duration of response (DOR) and progression-free survival (PFS) data in the frontline setting (43 patients) as well as updated clinical results in the recurrent setting (83 patients), at a medical meeting in the second quarter of 2026 ²⁴. The company believes silevertinib's ability to target approximately 50 oncogenic mutations not sufficiently addressed by existing therapies, along with its oral administration, tolerability profile, and CNS penetrance, offers significant potential. Following the updated data, the company expects to seek guidance from the FDA on a potential pivotal trial design in the frontline setting.

Another growth vector involves the GBM indication for silevertinib. Based on encouraging CNS activity observed in multiple trials, including an 86% CNS ORR in frontline EGFRm NSCLC patients ²⁵ and clinical activity in relapsed/recurrent GBM patients, silevertinib is positioned as a potential treatment for newly diagnosed EGFR-altered GBM. The planned randomized Phase 2 trial in this population, with interim efficacy data expected in the first half of 2028, aims to support a potential pivotal study. The eligible patient population for this trial will be EGFRvIII-positive patients (approximately 30% of GBM patients) who are O-6-methylguanine-DNA methyltransferase (MGMT)-negative (unmethylated) ²⁶.

Operationally, the company's strategy includes evaluating potential strategic partnerships for the pivotal development of silevertinib to maximize pipeline value and potentially secure non-dilutive funding. This includes exploring partnerships for a potential pivotal trial in frontline EGFRm NSCLC. The company also continues to review potential partnership opportunities and strategic alternatives for its FGFR program, BDTX-4876.

Regarding capital allocation, the company had cash, cash equivalents, and investments of $128.7 million ²⁷ as of December 31, 2025. Management believes these existing capital resources will be sufficient to fund anticipated operations into the second half of 2028 ²⁸. Future capital requirements will depend on the scope, progress, results, and costs of discovery, preclinical development, and clinical trials, as well as the costs of future commercialization activities and intellectual property protection.

Management explicitly flagged structural headwinds and execution risks, including the need for substantial additional funding, as the company expects expenses to increase with ongoing clinical development and potential commercialization. The company's ability to raise capital on acceptable terms is subject to market volatility and macroeconomic conditions. The recently enacted BIOSECURE Act has the potential to restrict the ability of U.S. biopharmaceutical companies to purchase services or products from, or collaborate with, certain Chinese biotechnology companies of concern, which could materially and adversely affect the company's or its collaborators' ability to manufacture or supply product candidates or advance clinical development programs.

Geographic, regulatory, and macro factors identified as constraints include the complex and evolving regulatory environment for drug approvals globally, with differing requirements and review periods outside the U.S. The company also highlighted the impact of the Inflation Reduction Act of 2022 (IRA) and the One Big Beautiful Bill Act of 2025 (OBBB Act) on drug pricing and Medicare programs, as well as potential future tariffs and trade restrictions, particularly with China, which could disrupt supply chains and increase costs. The U.S. Supreme Court's February 2026 ruling invalidating a significant portion of previously imposed tariffs and the Trump administration's intention to reinstate or impose new tariffs create uncertainty.

The company faces material risks including substantial dependence on its lead product candidate, silevertinib, with a high risk of failure in clinical development, regulatory approval, and commercialization. Difficulty in patient enrollment for clinical trials, particularly for genetically defined cancers, could cause delays. The company's novel approach to precision medicine is unproven and may not lead to marketable products, and market opportunities for product candidates may be small. Global events such as business, economic, or geopolitical disruptions, including high inflation, changing interest rates, and international tariffs, could harm development efforts and increase costs. The BIOSECURE Act, enacted on December 18, 2025, could restrict the company's ability to engage with certain biotechnology providers, potentially leading to supply chain disruptions or delays. Manufacturing is complex and reliant on third parties, posing risks of production difficulties, quality control issues, and supply disruptions. The company has no marketing and sales organization and faces substantial competition from major pharmaceutical and biotechnology companies. Intellectual property protection is uncertain, with risks of patent challenges, invalidation, or infringement claims, which could be costly and time-consuming. Changes in healthcare laws and regulations, including the Inflation Reduction Act of 2022 and the One Big Beautiful Bill Act of 2025, could lead to unfavorable pricing regulations, limited third-party coverage and reimbursement, and increased compliance costs. Cybersecurity incidents, including those facilitated by artificial intelligence, pose risks of data breaches and operational disruptions. The company's ability to utilize net operating loss carryforwards and other tax attributes may be limited by "ownership changes" under Sections 382 and 383 of the Internal Revenue Code, with gross U.S. federal net operating loss carryforwards of $322 million ²⁹, state net operating loss carryforwards of $221 million ³⁰, and U.S. federal research and development tax credit carryforwards of $13 million ³¹ as of December 31, 2025.

Management's message to shareholders emphasizes a vision to build a differentiated, global biopharmaceutical company focused on developing and commercializing novel medicines for patients with genetically defined tumors. They highlight the proprietary Mutation-Allostery-Pharmacology (MAP) drug discovery engine as the foundation for identifying novel oncogenic driver mutations and targeting families of oncogenic mutations with MasterKey therapies. The three strategic priorities for the period ahead are: generating Phase 2 clinical trial results for silevertinib in EGFRm NSCLC to enable a potential pivotal trial, conducting a Phase 2 clinical trial for silevertinib in newly diagnosed EGFR altered GBM patients to support a potential pivotal study, and evaluating potential strategic partnerships for the pivotal development of silevertinib and to maximize the value of the pipeline. Management explicitly states that existing capital resources of $128.7 million ³² as of December 31, 2025, are believed to be sufficient to fund anticipated operations into the second half of 2028 ³³.